# **Special Issue**

# Molecular Insights into HIV-1 Infection

## Message from the Guest Editor

The FDA's approval of Lenacapavir, a long-acting HIV-1 prevention drug has marked the year 2025 as a significant milestone in anti-retroviral therapy. Recent advancements and breakthroughs in HIV-1 molecular biology have intensified the race to achieve the development of a complete cure for AIDS. A better understanding of the complex interplay between virus and host cell factors at the molecular level will contribute to developing more effective therapeutic strategies. This Special Issue, "Molecular Insights into HIV-1 Infection", seeks manuscripts that investigate the crucial steps of the HIV-1 lifecycle; virus entry into host cell, nuclear trafficking, integration, latency, assembly, egress, and maturation. We additionally encourage the submission of papers that explore the latest technology in this field used to develop novel drug molecules or anti-HIV-1 strategies. Review articles on recent developments in our understanding of HIV-1 biology are also welcome. We look forward to receiving your submissions, hoping to contribute to the development of innovative strategies against HIV-1.

#### **Guest Editor**

Dr. Satya Prakash Singh

Department of Biological Science, Florida State University, Tallahassee, FL, USA

## Deadline for manuscript submissions

31 December 2026



## **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/250496

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





## Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

## **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

